Arcturus Therapeutics Holdings マネジメント
マネジメント 基準チェック /24
Arcturus Therapeutics Holdingsの CEO はJoe Payneで、 Mar2013年に任命され、 の在任期間は 11.67年です。 の年間総報酬は$ 4.89Mで、 14.3%給与と85.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.46%を直接所有しており、その価値は$ 25.27M 。経営陣と取締役会の平均在任期間はそれぞれ1.5年と5.8年です。
主要情報
Joe Payne
最高経営責任者
US$4.9m
報酬総額
| CEO給与比率 | 14.3% |
| CEO在任期間 | 11.7yrs |
| CEOの所有権 | 5.5% |
| 経営陣の平均在職期間 | 1.5yrs |
| 取締役会の平均在任期間 | 5.8yrs |
経営陣の近況
Recent updates
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Nov 14Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$107m |
| Dec 31 2023 | US$5m | US$698k | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$3m | US$425k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$26m |
| Jun 30 2018 | n/a | n/a | -US$25m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$449k | US$384k | -US$11m |
報酬と市場: Joeの 総報酬 ($USD 4.89M ) は、 US市場 ($USD 2.24M ) の同規模の企業の平均を上回っています。
報酬と収益: Joeの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Joe Payne (52 yo)
11.7yrs
在職期間
US$4,892,500
報酬
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 11.7yrs | US$4.89m | 5.46% $ 25.3m | |
| Founder | 11.8yrs | US$3.18m | 1.61% $ 7.4m | |
| CFO & Director | 6.3yrs | US$2.18m | 0.81% $ 3.8m | |
| Chief Legal Officer | 4.3yrs | US$2.10m | 0% $ 0 | |
| Vice President and Head of IR/PR & Marketing | no data | データなし | データなし | |
| Chief Human Resources Officer | 1.3yrs | データなし | データなし | |
| Chief Business Officer | 6.2yrs | データなし | データなし | |
| Chief Medical Officer | 1.5yrs | データなし | データなし | |
| Chief Development Officer | 1.5yrs | データなし | データなし | |
| Chief Strategy Officer | less than a year | データなし | データなし | |
| Chief Regulatory Officer | less than a year | データなし | データなし | |
| Controller | less than a year | データなし | データなし |
1.5yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: ARCTの経営陣は 経験豊富 とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 11.7yrs | US$4.89m | 5.46% $ 25.3m | |
| CFO & Director | 5.2yrs | US$2.18m | 0.81% $ 3.8m | |
| Independent Chairman of the Board | 6.5yrs | US$328.00k | 0.36% $ 1.7m | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | データなし | データなし | |
| Independent Director | 5.2yrs | US$325.50k | 0.012% $ 53.5k | |
| Independent Director | 6.5yrs | US$330.50k | 0.048% $ 224.2k | |
| Independent Director | 6.5yrs | US$318.00k | 0.10% $ 479.2k | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 9.9yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 9yrs | データなし | データなし | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 2.7yrs | US$644.00k | データなし | |
| Member of the Vaccine Platform Scientific Advisory Board | 4.3yrs | データなし | データなし |
5.8yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: ARCTの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。